Business
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening Session BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc.
About this update from Inmune Bio Inc.
[{"type":"text","content":"Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening Session BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio’s CSO, will be giving the opening plenary lecture of the Presidential Symposium at the International Society of Cell and Gene Therapy (ISCT) in Paris, France on May 31st. Dr. Lowdell’s lecture titled, “The Future of Immune Effector Cell Therapies for Cancer, Tumor-Primed Memory NK Cells – from Heresy to Clinical Trials,” will describe how INKmune™, INmune Bio’s proprietary Natural Killer (NK) cell platform, primes the patient’s NK cells to alter their phenotype to a cancer-killing population of memory-like NK cells that differ from single-cytokine or multiple-cytokine (IL-12, IL-15, IL-18) primed NK cells. The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer. Dr. Lowdell’s team at INmune Bio has shown that NK cells primed by INKmune™ or by the triple cytokine combination of IL12/15/18 (CIML-NK) consist of a complex mix of cell subsets with a unique memory associated phenotype. Using high-dimensional flow cytometry to simultaneously analyze 31 cell surface proteins, the team analyzed resting NK cells, IL-15 LAK (LAK=lymphokine activated killer cells), CIML-NK and INKmune-primed (TpNK) side-by-side. The data showed at least 8 clusters of NK cell types, one of which was restricted to CIML-NK and TpNK. This last cluster has never been described. “Whilst the existence of “memory-like” NK cells based on function has been known for over 10 years, it’s safe to say no-one has identified a unique cell surface phenotype for these cells,” said Dr. Lowdell. “Our interest in activating NK cells with INKmune™ to kill cancer provided a unique opportunity to better define these cells by comparison with CIML-NK.” The team has reported previously that TpNK function better in the hostile tumor microenvironment (TME) than CIML-NK or IL15 LAK because of upregulation of nutrient receptors and mitochondrial survival proteins leading to increased metabolic activity and resistance to exhaustion. “The latest data show that TpNK are at an intermediate stage between single-cytokine primed cells and CIML-NK. CIML-NK contains a l...